Di Ma

No. 1 DaHua Road
Beijing, 100730, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients.

Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients.

Journal: BMC cancer

Published: November 20, 2024

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.

Journal: World journal of surgical oncology

Published: May 09, 2023

TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy.

TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy.

Journal: Cancers

Published: June 13, 2022

Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.

Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.

Journal: Thoracic cancer

Published: April 17, 2022

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study.

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: July 30, 2019

Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment.

Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: June 04, 2019

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.

Journal: Targeted oncology

Published: May 25, 2019

Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.

Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.

Journal: Targeted oncology

Published: April 27, 2019

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib.

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib.

Journal: Cancer management and research

Published: April 26, 2019

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study.

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study.

Journal: Cancer medicine

Published: March 20, 2019

Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer

Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: March 05, 2019

Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.

Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.

Journal: Thoracic cancer

Published: February 24, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026